UK – NICE rejects Janssen’s Stelara on cost efficiency grounds

The National Institute for Health and Care Excellence (NICE) has released a draft guidance not recommending Janssen’s Stelara (ustekinumab) for moderately to severely active ulcerative colitis in adults.

Despite there being an unmet need for new, non-surgical treatment options because many people have an inadequate response to current therapies or they stop working, the organisation said there is considerable uncertainty about the cost-effectiveness estimates for the drug.

NICE said that it already recommends several treatment options for when conventional therapy or a biological agent cannot be tolerated, or the disease has responded inadequately or lost response to treatment.

If approved, Stelara would be used when conventional therapy or a biological agent cannot be tolerated or the disease has responded inadequately or lost response to treatment…